Ligand Income Before Tax vs Operating Income Analysis
LGND Stock | USD 86.06 1.04 1.22% |
Ligand Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Ligand Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Ligand Pharmaceuticals is a good investment. Please check the relationship between Ligand Pharmaceuticals Income Before Tax and its Operating Income accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Ligand Pharmaceuticals Incorporated. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
Income Before Tax vs Operating Income
Income Before Tax vs Operating Income Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Ligand Pharmaceuticals Income Before Tax account and Operating Income. At this time, the significance of the direction appears to have no relationship.
The correlation between Ligand Pharmaceuticals' Income Before Tax and Operating Income is 0.01. Overlapping area represents the amount of variation of Income Before Tax that can explain the historical movement of Operating Income in the same time period over historical financial statements of Ligand Pharmaceuticals Incorporated, assuming nothing else is changed. The correlation between historical values of Ligand Pharmaceuticals' Income Before Tax and Operating Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Income Before Tax of Ligand Pharmaceuticals Incorporated are associated (or correlated) with its Operating Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Operating Income has no effect on the direction of Income Before Tax i.e., Ligand Pharmaceuticals' Income Before Tax and Operating Income go up and down completely randomly.
Correlation Coefficient | 0.01 |
Relationship Direction | Positive |
Relationship Strength | Insignificant |
Income Before Tax
Income Before Tax which can also be referred as pre-tax income is reported on Ligand Pharmaceuticals income statement and is an important metric when analyzing Ligand Pharmaceuticals profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.Operating Income
Operating Income is the amount of profit realized from Ligand Pharmaceuticals operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Ligand Pharmaceuticals Incorporated is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.Most indicators from Ligand Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Ligand Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Ligand Pharmaceuticals Incorporated. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. At present, Ligand Pharmaceuticals' Sales General And Administrative To Revenue is projected to increase slightly based on the last few years of reporting. The current year's Enterprise Value Over EBITDA is expected to grow to 39.45, whereas Selling General Administrative is forecasted to decline to about 49.7 M.
2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 136.1M | 140.4M | 109.9M | 98.8M | Cost Of Revenue | 62.2M | 52.8M | 11.6M | 18.5M |
Ligand Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Ligand Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Ligand Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 1.5B | 1.4B | 1.3B | 762.7M | 833.1M | 453.0M | |
Short Long Term Debt Total | 648.9M | 454.5M | 336.3M | 87.7M | 6.2M | 5.9M | |
Other Current Liab | 11.2M | 60.3M | 22.2M | 21.0M | 256K | 243.2K | |
Total Current Liabilities | 17.0M | 100.1M | 41.7M | 98.8M | 16.8M | 15.9M | |
Total Stockholder Equity | 767.2M | 709.5M | 821.6M | 597.5M | 700.9M | 736.0M | |
Property Plant And Equipment Net | 10.4M | 22.7M | 32.7M | 15.0M | 9.5M | 8.3M | |
Net Debt | (362.6M) | 406.9M | 316.7M | 87.7M | (16.8M) | (15.9M) | |
Retained Earnings | 400.1M | 392.0M | 449.1M | 450.9K | 503.0M | 528.2M | |
Accounts Payable | 2.4M | 3.8M | 8.4M | 5.3K | 14.9M | 11.9M | |
Cash | 1.0B | 47.6M | 19.5M | 45.0K | 23.0M | 21.8M | |
Non Current Assets Total | 345.7M | 861.7M | 836.6M | 499.1M | 595.6M | 625.4M | |
Non Currrent Assets Other | 9.5M | 18.7M | 23.3M | 14.2M | 21.5M | 22.6M | |
Cash And Short Term Investments | 1.1B | 411.2M | 341.1M | 211.9M | 170.3M | 177.7M | |
Net Receivables | 41.7M | 59.1M | 91.6M | 35.0M | 39.3M | 22.8M | |
Common Stock Shares Outstanding | 19.8M | 16.2M | 17.2M | 16.9M | 17.8M | 16.2M | |
Liabilities And Stockholders Equity | 1.5B | 1.4B | 1.3B | 762.7M | 833.1M | 453.0M | |
Non Current Liabilities Total | 685.1M | 552.6M | 438.1M | 66.4M | 113.9M | 180.2M | |
Other Current Assets | 4.7M | 3.8M | 4.7M | 3.4M | 3.8M | 3.6M | |
Other Stockholder Equity | 367.3M | 318.4M | 373.4M | 597.0M | 198.7M | 188.8M | |
Total Liab | 702.1M | 652.8M | 479.8M | 165.2M | 130.7M | 256.0M | |
Property Plant And Equipment Gross | 17.5M | 21.3M | 32.7M | 15.0M | 31.7M | 33.3M | |
Total Current Assets | 1.1B | 500.6M | 464.8M | 263.6M | 237.4M | 218.7M | |
Accumulated Other Comprehensive Income | (216K) | (801K) | (917K) | (984.0) | (817K) | (857.9K) | |
Short Term Debt | 1.2M | 6.6M | 46K | 77.4M | 410K | 389.5K | |
Inventory | 7.3M | 26.5M | 27.3M | 13.3M | 24.0M | 25.2M | |
Short Term Investments | 58.3M | 363.6M | 321.6M | 166.9K | 147.4M | 154.7M | |
Other Liab | 61.8M | 104.7M | 101.9M | 56.0M | 64.4M | 43.3M | |
Other Assets | 28.0M | 62.3M | 58.8M | 13.3M | 15.3M | 14.5M | |
Long Term Debt | 609.9M | 639.0M | 442.3M | 320.7M | 368.8M | 387.3M | |
Intangible Assets | 20.1M | 11.0M | 10.1M | 10.2M | 366.9M | 385.2M | |
Property Plant Equipment | 7.2M | 14.4M | 32.7M | 27.5M | 31.6M | 33.2M | |
Current Deferred Revenue | 2.1M | 29.4M | 11.0M | 355K | 1.2M | 1.2M | |
Good Will | 305.7M | 785.0M | 735.0M | 448.1M | 103.4M | 98.2M | |
Retained Earnings Total Equity | (229.2M) | 400.1M | 392.0M | 449.1M | 516.5M | 542.3M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.C | Citigroup | |
CRM | Salesforce | |
MSFT | Microsoft |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Ligand Pharmaceuticals Incorporated. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Complementary Tools for Ligand Stock analysis
When running Ligand Pharmaceuticals' price analysis, check to measure Ligand Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ligand Pharmaceuticals is operating at the current time. Most of Ligand Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ligand Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ligand Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ligand Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |
Is Ligand Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ligand Pharmaceuticals. If investors know Ligand will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ligand Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.032 | Earnings Share 5.35 | Revenue Per Share 6.774 | Quarterly Revenue Growth (0.30) | Return On Assets (0) |
The market value of Ligand Pharmaceuticals is measured differently than its book value, which is the value of Ligand that is recorded on the company's balance sheet. Investors also form their own opinion of Ligand Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ligand Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ligand Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ligand Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ligand Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ligand Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ligand Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.